Pharnext: New approach in the treatment of Alzheimer’s disease

A French biopharmaceutical company focused on neurodegenerative diseases Pharnext, said that testing of a Pleodrug being developed for the treatment of Alzheimer’s disease (AD), show positing efficiacy of PXT864 for further studies such as an international multicenter adaptive-design Phase 2 study.

The presentation was held at the 9^th Clinical Trials on Alzheimer’s Disease (CTAD) conference, on December 8-10, 2016 in USA’s San Diego.

Daniel Cohen, M.D., Ph.D., Co-Founder and Chief Executive Officer of Pharnext, said: “We believe that these findings bring new evidence of PXT864 safety and efficacy in patients suffering from mild stages of Alzheimer’s disease and this clinical trial has the potential to be a key turning point in the effort to finally provide an efficacious treatment for these patients. These data also further validate our Pleotherapy research and development approach and we hope to provide novel treatments for many diseases via such synergic drug combinations.”

René Goedkoop, M.D., Chief Medical Officer of Pharnext added, “The data presented provide encouraging evidence for PXT864 as an entirely new approach in the treatment of Alzheimer’s disease. Today there are no treatments capable of altering the progressive course of this terrible disease. We look forward to the continuation of PXT864 clinical development and hope that we can bring an efficacious treatment to people suffering from Alzheimer’s disease and to improve their quality of life.”